secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2026-09-29T11:05:31+00:00
Accession:  0001104659-26-111583
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Iovance raises FY2026 revenue guidance to $410-$420M from $350-$370M on Amtagvi, Proleukin demand
--------------------------------------------------------------------------------

- FY2026 total revenue guidance raised to $410-$420M, up $55M (~15%) at the midpoint from the prior $350-$370M range; implies nearly 60% annual growth.
- Iovance most recently reported record Q2 2026 total product revenue of $99.3M, driven by strong U.S. demand for Amtagvi (lifileucel) and Proleukin.
- Authorized treatment center (ATC) network has grown to ~100 centers, with expansion to at least 110 ATCs expected by year-end 2026.
- Interim CEO Frederick Vogt cites current manufacturing schedule as giving strong visibility into Q3 and Q4 revenues, plus efficiencies accelerating progress toward profitability.
- Q3 2026 financial results expected in early November 2026; this update completes the guidance review announced with Q2 results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465926111583/0001104659-26-111583-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465926111583/tm2626507d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-111583

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer